Results 171 to 180 of about 377,050 (209)

Differential inhibition of human secretory and cytosolic phospholipase A2

Agents and Actions, 1993
The roles and relative contributions of secretory and cytosolic phospholipases A2 in physiology and pathology are not precisely known. In a search for differential inhibitors of these enzymes, which could serve as tools to clarify this issue, we evaluated the potencies of reference compounds and three series of new compounds, viz.
F, Märki, W, Breitenstein, E, Beriger, R, Bernasconi, G, Caravatti, J E, Francis, R, Paioni, H U, Wehrli, R, Wiederkehr   +8 more
openaire   +2 more sources

Class specific peptide inhibitors for secretory phospholipases A2

Biochemical and Biophysical Research Communications, 2013
Phospholipases A2 (PLA2) catalyze the hydrolytic cleavage of free fatty acids from the sn-2 OH-moiety of glycerophospholipids. These enzymes have a number of functions, from digestion to signaling and toxicity of several venoms. They have also been implicated in inflammation and are connected to diverse diseases, such as cancer, ischemia ...
Mahalka, Ajay K, Kinnunen, Paavo, KJ
openaire   +3 more sources

Secretory phospholipase A2: A multifaceted family of proatherogenic enzymes

Current Cardiology Reports, 2009
Secretory phospholipase A(2) (sPLA(2)) represents a class of enzymes that hydrolyze phospholipids from cellular membranes and lipoproteins, resulting in multifarious proatherogenic actions in the vessel wall. Proatherogenic actions of sPLA(2) involve lipoprotein remodeling that facilitates proteoglycan binding and formation of lipid aggregates that are
Robert S, Rosenson, Michael H, Gelb
openaire   +2 more sources

Secretory phospholipase A2 in patients with coronary artery disease

Journal of Thrombosis and Thrombolysis, 2009
This study investigated the correlation of sPLA2 (secretory phospholipase A2) activity with the atheromatosis extent in subjects with coronary artery disease (CAD) undergoing coronary angiography. We analyzed 123 patients, including 35 subjects with angiographically normal coronary arteries (controls), 31 with mild/moderate atheromatosis (stenosis of ...
Luciana Moreira, Lima, Maria das Graças, Carvalho, Cirilo Pereira, da Fonseca Neto, José Carlos Faria, Garcia, Marinez Oliveira, Sousa   +4 more
openaire   +2 more sources

Inhibitors of Secretory Phospholipase A2 Group IIA

Current Medicinal Chemistry, 2005
Phospholipases A2 cleave membrane phospholipids to release arachidonic acid, the precursor to a large family of pro-inflammatory eicosanoids including prostaglandins and leukotrienes that have been proven to exacerbate numerous diseases that have an inflammatory component. Current therapies include NSAIDs that inhibit cyclooxygenases (COX-1, COX-2)
openaire   +5 more sources

Reversible activation of secretory phospholipase A2 by sulfhydryl reagents

Archives of Biochemistry and Biophysics, 2005
Secretory phospholipase A(2)s (sPLA(2)s) have been implicated in physiological and pathological events, but the regulatory mechanism(s) of their activities in cells remains to be solved. Previously, we reported that phenylarsine oxide (PAO), a sulfhydryl reagent, stimulated arachidonic acid (AA) release in rat pheochromocytoma PC12 cells. In this study,
Maiko, Nabemoto, Keiko, Ohsawa, Hiroyuki, Nakamura, Tetsuya, Hirabayashi, Takeshi, Saito, Yasunobu, Okuma, Yasuyuki, Nomura, Toshihiko, Murayama   +7 more
openaire   +2 more sources

CHARACTERIZATION OF NUCLEAR SECRETORY PHOSPHOLIPASE A2 (sPLA2)

2005
The presence of phospholipase A (PLA ) activities in mammalian 22 brain has been reported in several studies (Farooqui et al., J. Neu- rochem. 69:889, 1997). The identity and subcellular distribution of various enzymes, belonging to different groups (G), are still largely unknown.
NARDICCHI, Vincenza, MACCHIONI, Lara, FERRINI, Monica, BIANCONI, Marcello, GORACCI, Gianfrancesco   +4 more
openaire   +2 more sources

Expression of secretory phospholipase A2s in human atherosclerosis development

Atherosclerosis, 2008
Secretory phospholipase A2s (sPLA2s) contribute to the hydrolysis of phospholipid. Among them, sPLA2-IIA, -V, and -X have been regarded as enhancers of lipid accumulation in arterial intima. However, the distribution and production of the other types of sPLA2 in human aortic wall remain unclear. Therefore, in this study, the distribution and production
Masayo, Kimura-Matsumoto, Yukio, Ishikawa, Kazuo, Komiyama, Tadashi, Tsuruta, Makoto, Murakami, Seiko, Masuda, Yoshikiyo, Akasaka, Kinji, Ito, Shigeki, Ishiguro, Hiroshi, Morita, Shinji, Sato, Toshiharu, Ishii   +11 more
openaire   +2 more sources

Expression of inflammatory secretory phospholipase A2 and cytosolic phospholipase A2 in premalignant and malignant Barrett?s oesophagus

Virchows Archiv, 2004
To establish the prevalence of inflammatory secretory phospholipase A2 (sPLA2) and cytoplasmic phospholipase A2 (cPLA2) expression in a surgical series of Barrett's adenocarcinoma and associated preneoplastic lesions and to correlate this expression with clinicopathological data and prognosis.sPLA2 and cPLA2 were analysed by means of ...
Christine, Lagorce-Pagès, François, Paraf, Dominique, Wendum, Antoine, Martin, Jean-François, Fléjou   +4 more
openaire   +2 more sources

Diversity and regulatory functions of mammalian secretory phospholipase A2s

2001
Publisher Summary This chapter introduces the recent advances in the diversity, enzymatic properties, and functions of the sPLA 2 family emphasizing particularly on the roles of each sPLA 2 in eicosanoid generation in the context of functional coupling between other eicosanoid-biosynthetic enzymes in different phases of cell activation.
M, Murakami, I, Kudo
openaire   +2 more sources